MCF Advisors LLC Sells 204,170 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX)

MCF Advisors LLC lowered its stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) by 82.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 42,854 shares of the company’s stock after selling 204,170 shares during the quarter. MCF Advisors LLC’s holdings in Poseida Therapeutics were worth $411,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in PSTX. The Manufacturers Life Insurance Company boosted its holdings in Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after buying an additional 3,552 shares during the period. Rhumbline Advisers lifted its position in shares of Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after acquiring an additional 3,875 shares in the last quarter. Brooklyn Investment Group bought a new position in shares of Poseida Therapeutics in the fourth quarter worth about $40,000. American Century Companies Inc. grew its position in shares of Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after purchasing an additional 5,023 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Poseida Therapeutics by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after purchasing an additional 9,672 shares during the period. 46.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PSTX shares. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. HC Wainwright restated a “neutral” rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target on the stock. in a report on Monday, December 2nd. Cantor Fitzgerald cut Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 26th. Finally, BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.50.

Poseida Therapeutics Price Performance

Poseida Therapeutics stock opened at $9.50 on Wednesday. The firm’s fifty day moving average is $8.16 and its 200 day moving average is $4.77. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market cap of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63. Poseida Therapeutics, Inc. has a 52-week low of $1.87 and a 52-week high of $9.67.

Poseida Therapeutics (NASDAQ:PSTX) last announced its earnings results on Thursday, November 7th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.63. The business had revenue of $71.75 million for the quarter, compared to the consensus estimate of $15.00 million. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. Sell-side analysts forecast that Poseida Therapeutics, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total transaction of $278,100.00. Following the transaction, the chairman now owns 651,291 shares of the company’s stock, valued at approximately $6,037,467.57. This trade represents a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.90% of the company’s stock.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.